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Partner Site Gießen-Marburg-Langen, Giessen, GermanyAbstractHepatitis B core-related antigen (HBcrAg) has been suggested as an additional marker of hepatitis B virus (HBV) infection. HBcrAg combines
the antigenic reactivity resulting from denatured hepatitis B e antigen (HBeAg), HBV core antigen and an artiﬁcial core-related protein
(p22cr). In Asian patients, high levels of HBcrAg have been suggested to be an independent risk factor for hepatocellular carcinoma,
while low levels could guide safe cessation of treatment with nucleos(t)ide analogues. We here studied HBcrAg levels in different phases
of HBV infection in a large European cohort predominantly infected with genotypes A and D: HBeAg-positive immune tolerance
(n = 30), HBeAg-positive immune clearance (IC) (n = 60), HBeAg-negative hepatitis (ENH) (n = 50), HBeAg-negative inactive/quiescent
carrier phase (c) (n = 109) and acute hepatitis B (n = 8). Median HBcrAg levels were high in the immune tolerance and immune
clearance phases (8.41 and 8.11 log U/mL, respectively), lower in ENH subjects (4.82 log U/mL) but only 2.00 log U/mL in ENQ subjects.
Correlation between HBcrAg and HBV DNA varied among the different phases of HBV infection, while HBcrAg moderately correlated
with hepatitis B surface antigen in all phases. ENQ patients had HBcrAg levels <3 log U/mL in 79%, in contrast to only 12% in the ENH
group. HBcrAg levels vary signiﬁcantly during the different phases of HBV infection. HBcrAg may serve as valuable marker for virus
replication and reﬂect the transcriptional activity of intrahepatic cccDNA. In HBeAg-negative patients, HBcrAg may help to distinguish
between inactive carriers (ENQ) and those with active disease (ENH).
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p://dx.doi.org/10.1016/j.cmi.2015.02.010IntroductionHepatitis B virus (HBV) infection is a global health burden, with
more than 350 million chronically infected individuals world-
wide [1]. Chronic hepatitis B progresses to liver cirrhosis in
infected individuals in about 8% to 20% within 5 years. In
addition, the 5-year prevalence of hepatocellular carcinoma
(HCC) is estimated to be 10% to 17% in cirrhotic patients, butious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Maasoumy et al. HBcrAg levels HBV infection 606.e2importantly, HCC may also occur in HBV patients without any
signs of liver cirrhosis [1–3]. However, not all patients with
chronic HBV infection develop liver cirrhosis and/or HCC.
Thus, it is of major importance to identify patients who are at
risk in order to decide who requires a closer monitoring or
antiviral treatment. HBV infection may follow different phases
during the natural history of the disease: a hepatitis B e antigen
(HBeAg)-positive immune tolerance (IT) phase, an HBeAg-
positive immune clearance (IC) phase, an HBeAg-negative
inactive/quiescent carrier phase (ENQ) and HBeAg-negative
hepatitis (ENH) [1–3]. Antiviral treatment is usually only indi-
cated in patients with active hepatitis (IC and ENH phases)
[1,3].
Different well-established serologic and molecular parame-
ters are used to diagnose HBV infection, to determine the
phase of HBV infection, to stratify the risk for liver cirrhosis or
HCC and to monitor antiviral therapy. Currently, most treat-
ment guidelines focus on quantitative HBV DNA as a marker
for the need to deliver antiviral therapy, as it has been shown in
large cohorts that the risk for HCC correlates with the HBV
DNA serum level [4]. Moreover, the degree of liver disease
indicated by alanine aminotransferase (ALT) levels or assessed
by liver biopsy is important to select patients for treatment [1].
However, recently it has been shown that HCC prediction as
well as the correct classiﬁcation of ENQ can be widely
improved by including additional markers during the evaluation
of patients. In particular, quantitative hepatitis B surface antigen
(qHBsAg) seems to be of high value [5–7]. HBsAg levels vary
among the different phases of HBV infection [5,6] and are
helpful to differentiate patients with ENH from inactive carrier
patients [5,7]. Several other markers are currently under
investigation in order to further improve our understanding of
HBV infection and to better deﬁne treatment indications.
Hepatitis B core-related antigen (HBcrAg) has been sug-
gested as another serologic marker of HBV infection besides
qHBsAg and virus DNA. HBcrAg combines the antigenic
reactivity resulting from denatured HBeAg, HBV core antigen
(HBcAg) and a core-related protein (p22cr), found in virionlike
particles without HBV DNA [8]. HBcAg, HBeAg and the p22cr
protein are all products of the precore/core gene [9] and share
an identical 149 long amino acid sequence, which can be
detected by HBcrAg assays. HBcrAg levels were associated
with important clinical end points and other serologic markers
of HBV infection. HBcrAg levels >3 log U/mL but not qHBsAg
were an independent risk factor for the occurrence of HCC in
a large cohort of HBV patients from Japan [10]. Furthermore, it
has been shown that HBcrAg levels correlate with HBV DNA
as well as intrahepatic cccDNA [19]. In addition, during treat-
ment with nucleos(t)ide analogues (NA), the decline of HBcrAg
levels correlated with the decrease of cccDNA and HBV DNAClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inf[12]. High HBcrAg levels during NA treatment were identiﬁed
as a risk factor for the occurrence of virus resistance to lam-
ivudine, while in small studies from Japan a low HBcrAg also
was the only valuable marker to indicate a safe cessation of
lamivudine therapy [13–15]. Most recently, Seto and colleagues
analysed HBcrAg in the natural history of chronic HBV infec-
tion, demonstrating that HBcrAg may help to distinguish be-
tween HBeAg-negative patients with active disease and inactive
carriers [16]. However, so far, all data on HBcrAg are entirely
limited to Asian patients who are mainly vertically infected with
HBV genotypes B or C.
We here aimed to investigate HBcrAg serum levels in the
different phases of hepatitis B for the ﬁrst time in a large Eu-
ropean cohort mainly infected with HBV genotypes A or D.Patients and methodsPatients
We tested 249 blood samples of HBsAg-positive patients in
different phases of chronic HBV infection and 38 samples ob-
tained from eight patients at different time points during acute
hepatitis B who were seen at Hannover Medical School be-
tween 1996 and 2012. None of the patients underwent antiviral
therapy when their blood sample was obtained. All samples
were stored at −20°C.
Deﬁnition of the different phases of chronic HBV
infection
Phase of HBV infection was determined using HBV DNA and
ALT serum levels according to the current guidelines from the
European Association for the Study of the Liver (EASL) and the
German national guideline for the management of HBV infec-
tion [1,3]. Four different phases were deﬁned: an HBeAg-
positive high replicative carrier phase (IT), IC, ENQ and
ENH. The detailed criteria that were applied can be found in
Supplementary Table S1.
Measurement of clinical parameters
The Abbott ARCHITECT assay (Abbott Diagnostics, Abbott
Park, IL, USA) was used for HBsAg quantiﬁcation. The assay has
a dynamic range of 0.05 to 250 IU/mL. If qHBsAg results were
>250 IU/mL, samples were retested at a dilution of 1:500.
Samples with HBsAg levels <0.05 IU/mL were retested without
prior dilution. The inter- and intra-assay variability is below 10%
(6.7% to 8.8%), according to the manufacturer data sheet. We
used the COBAS AmpliPrep/COBAS TaqMan (Roche Di-
agnostics, Mannheim, Germany) and the TaqMan Universal
Master Mix (Applied Biosystems, Foster City, CA, USA) for the
measurement of HBV DNA levels. The assays limits ofectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 606.e1–606.e10
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otyping was performed as previously described [5]: We used a
modiﬁed restriction fragment length polymorphism PCR assay
with ampliﬁed HBV DNA by use of a nested PCR. Sequences
were matched with the National Center for Biotechnology
Information GenBank and compared to described HBV pro-
totypes (accession numbers: HBV-A, Z72478; HBV-B, D00329;
HBV-C, X01587; HBV-D, V01460). The HBV S sequences and
related references sequences were aligned with CLC Main
Workbench 6 (CLCBio, Aarhus, Denmark). Bootstrap resam-
pling and reconstruction were carried out 1000 times [5]. ALT,
aspartate aminotransferase (AST), alkaline phosphatase (AP),
γ-glutamyl transferase (yGT), albumin and bilirubin were
measured in the central laboratory of Hannover Medical
School. Local upper limits of normal were used for the
following calculations.
Measurement of serum HBcrAg levels
Quantitative levels of HBV core-related antigen (HBcrAg) were
determined using the Lumipulse G HBcrAg assay (Fujirebio
Europe, Gent, Belgium), which measures simultaneously dena-
tured HBeAg, HBcAg and the precore protein p22cr (aa −28 to
aa 150). Samples were handled according to the manufacturer’s
instructions. HBcrAg levels are quantiﬁed in U/mL. The total of
1 U/mL is deﬁned by immunoreactivity of recombinant pro-
HBe antigen at 10 fg/mL [14]. The assay’s validated measure-
ment range is from 3 log to 7 log U/mL. However, the machine
indicates levels lower than 3 log U/mL down to 2 log U/mL in
HBcrAg-positive samples [16]. In cases of HBcrAg levels below
2 log U/mL (HBcrAg not detected by the HBcrAg assay), it is
not possible to distinguish between HBcrAg-negative samples
and HBcrAg detectable but not quantiﬁable samples. HBcrAg
levels below 2 log U/mL were calculated as 2 log U/mL for
statistical analysis. Samples with HBcrAg above 7 log U/mL
were diluted with horse serum and retested in order to
calculate the quantitative HBcrAg level.
Detection of HBV precore stop codon 28 mutation
The INNO-LiPA HBV PreCore assay (Fujirebio Europe) was
used to determine precore codon 28 wild-type or stop codon
mutants following the manufacturer’s instructions.
Statistical analysis
All data are provided as median and range unless otherwise
stated. Correlation was tested with the Spearman correlation
test. For univariate analyses, we applied the Mann-Whitney U
test for continuous data and Fisher’s exact test for categorical
data. Multivariate analyses were done with the Kruskal-Wallis
ANOVA. p values of <0.05 were considered to be statistically
signiﬁcant. Receiver operating characteristic (ROC) curvesClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwere generated to deﬁne optimal thresholds. We used
Microsoft Excel for Mac 2011 (Microsoft, Redmond, WA, USA)
for data collection and GraphPad Prism for Mac v6.0 (GraphPad
Software, La Jolla, CA, USA) to analyse the data.
Ethics
This study was performed according to the Declaration of
Helsinki. All patients provided informed consent for the analysis
of parameters assessed in stored blood samples taken during
routine diagnostics. Data were analysed anonymously. The local
ethical committee of Hannover Medical School approved the
retrospective, anonymous retesting of patient samples and the
anonymous analysis of patient data.ResultsCharacteristics of the included patients with chronic
HBV infection
There were signiﬁcant differences in the patients’ characteris-
tics between the different phases of HBV infection, reﬂecting
the applied criteria to deﬁne the respective phase. Patients in
the IT phase were younger compared to consecutive phases of
HBV infection. Median HBsAg levels were the highest in the IT
group (5.08 log IU/mL), as previously described [5]. Median
bilirubin, ALT and AST were higher in the IC and ENH phases,
which are, however, deﬁned by an inﬂammatory response of
the host immune system. Detailed patient characteristics are
shown in Table 1.
Distribution of serum HBcrAg levels during the
different phases of chronic HBV infection
Serum HBcrAg levels varied signiﬁcantly between the different
phases of chronic HBV infection. The highest HBcrAg levels
were documented in HBeAg-positive patients with signiﬁcantly
higher levels in the HBeAg-positive IT compared to the IC
group (median log U/mL: 8.41 and 8.11, respectively; p = 0.017)
(Fig. 1a). Lower HBcrAg levels were observed in the HBeAg-
negative group. Here, ENH patients had higher HBcrAg
serum levels compared to inactive/quiescent carriers (median
log U/mL: 4.82 and 2.00, respectively; p < 0.0001).
All HBeAg-positive IT patients had HBcrAg levels 7 log U/
mL, with the vast majority having levels 8 log U/mL, while
there was a wider distribution in the IC and ENH groups. In
contrast, most of those identiﬁed as ENQ had HBcrAg levels
below 3 log U/mL (79%). Importantly, ENH patients (although
also HBeAg-negative subjects) had HBcrAg levels <3 log U/mL
in only 12% of cases (Fig. 1b). ROC curve analysis revealed an
area under the curve for HBcrAg in distinguishing ENH from
ENQ of 0.87 (p < 0.0001).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 606.e1–606.e10
TABLE 1. Characteristics of patients with chronic HBV infection
Phase
IT IC ENH ENQ
p*(n [ 30) (n [ 60) (n [ 50) (n [ 109)
Age (years), median (range) 17 (1–35) 27.5 (7–68) 38 (9–67) 40 (12–67) <0.0001
Gender (%), M/F 57%/43% 75%/25% 72%/28% 45%/55% 0.0576
HBV DNA (log IU/mL), median (range) 8.46 (7.48–9.67) 8.04 (3.51–9.76) 5.44 (3.37–8.78) 2.71 (0–4.27) <0.0001
HBV genotype, n (%) 0.0164
A 1 (3%) 18 (30%) 12 (24%) 17 (16%)
D 29 (97%) 34 (57%) 33 (66%) 43 (39%)
NA 0 (0%) 8 (13%) 5 (10%) 49 (45%)
HBsAg (log IU/mL), median (range) 5.08 (4.21–5.84) 4.38 (3.37–5.83) 3.84 (1.83–4.84) 3.35 (0–4.84) <0.0001
HBcrAg (log U/mL), median (range) 8.41 (7.42–9.61) 8.11 (4.57–10.34) 4.82 (2.00–7.73) 2.00 (2.00–5.35) <0.0001
ALT/ULN, median (range) 0.84 (0.31–1.73) 3.84 (0.93–61.59) 2.27 (1.0–28.56) 0.68 (0.33–1.12) <0.0001
AST/ULN, median (range) 0.86 (0.23–1.97) 1.99 (0.86–36.44) 1.75 (0.83–22.83) 0.77 (0.34–1.77) <0.0001
GGT/ULN, median (range) 0.33 (0.15–1.89) 0.73 (0.13–11.46) 0.82 (0.2–3.84) 0.39 (0.16–2.89) <0.0001
Platelets (103/μL) median (range) 230 (15–401) 201 (70–726) 188.5 (46–310) 219.5 (53–512) 0.0022
Albumin (g/L), median (range) 41 (25–67) 40 (24–76) 40 (29–49) 42 (28–48) 0.6439
Bilirubin (μmol/L), median (range) 7 (3–27) 8.5 (3–224) 12 (4–24) 8 (3–40) 0.0050
HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; IT, immune tolerance; IC, immune clearance; ENH, HBeAg-negative hepatitis; ENQ, HBeAg-negative inactive/quiescent carrier
phase; NA, nucleos(t)ide analogues; HBsAg; HBcrAg; ULN, upper limit of normal; ALT, aspartate aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase.
* Kruskal-Wallis ANOVA.
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and D, we found a trend for higher HBcrAg levels in genotype
D patients in the IC and ENH phases. However, this was not
statistically signiﬁcant (p = 0.07 and 0.28, respectively) (Fig. 1c).
Only a single patient in the HBeAg-positive IT cohort was
infected with genotype A. Thus, we were not able to perform a
reliable analysis concerning the impact of HBV genotypes A or
D in this phase. In the ENQ subjects, there was no difference in
HBcrAg levels between genotypes A and D (median HBcrAg
levels: 2.00 and 2.00 log U/mL, respectively; p = 0.997) (Fig. 1c).
Correlation of HBcrAg with HBV DNA in the different
phases of chronic HBV infection
Overall, HBcrAg showed a strong correlation with HBV DNA
levels (r = 0.87; p < 0.0001) (Fig. 2a). However, correlation be-
tween the twomarkerswidely varied between the different phases
of HBV infection. While correlation was quite strong in ENH and
IC patients (r = 0.74 and 0.66, respectively; p < 0.0001), it was
weaker, although still statistically signiﬁcant, during the HBeAg-
positive IT phase (r = 0.45; p = 0.0130). In contrast, no statisti-
cally signiﬁcant correlations between HBV DNA and HBcrAg
levels were found in ENQ subjects (r = 0.18; p = 0.054) (Fig. 2a).
We further investigated the impact of the HBV genotype A
or D on the correlation between the two markers during the
natural course of chronic HBV infection (Fig. 2b). While the
correlation between HBV DNA and HBcrAg levels was strong
during the ENH phase in both HBV genotype A– and genotype
D– infected patients (r = 0.86 and 0.74, respectively), there was
quite a remarkable difference in IC patients. Here the corre-
lation was strong in genotype A– infected patients but much
weaker in genotype D– infected individuals (r = 0.82 and 0.34,
respectively). In contrast, in the ENQ subjects, we observed in
neither genotype A nor D patients a correlation between HBV
DNA and HBcrAg (Fig. 2b).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfCorrelation of HBcrAg with HBsAg during the
different phases of chronic HBV infection
The overall correlation of HBcrAg levels with qHBsAg was
strong in this study (r = 0.78; p < 0.0001) (Fig. 3a). In contrast
to the observed relation to HBV DNA, the correlation with
HBsAg was less effected by the respective phase of HBV
infection. Correlation between HBsAg and HBcrAg reached
statistical signiﬁcance in all phases of chronic HBV infection.
Correlation was moderate in all phases (Fig. 3a).
Interestingly, the present HBV genotype inﬂuenced the
relation between the two markers in the different phases of
HBV infection. In ENH and ENQ subjects, HBsAg and HBcrAg
correlated only in those infected with HBV genotype D but
not in those with genotype A. In contrast, correlation was
signiﬁcant for both HBV genotypes A and D in the IC group
(Fig. 3b).
Among the ENH patients, in whom we could detect HBV
precore stop mutants (at codon 28) but no wild-type variant,
resulting in HBeAg-negative phenotype, correlation between
HBcrAg and HBsAg was strong (r = 0.73; p < 0.0001), while
there was no correlation between HBsAg and HBcrAg in ENH
patients, in whom we exclusively detected precore wild-type
HBV (r = 0.17; p = 0.5169). Precore stop mutants were
frequent among ENH patients infected with genotype D (79%)
but rarely identiﬁed in those with genotype A (17%). We did
not observe a statistically signiﬁcant impact of precore mutation
status and the correlation between HBsAg and HBcrAg in ENQ
subjects (data not shown).
Correlation of HBcrAg with various other clinical
markers of liver disease
HBcrAg levels showed no close link to other clinical parame-
ters of liver disease in the HBeAg-positive IT and ENQ subjects.
In contrast, in ENH patients there was a moderate correlationectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 606.e1–606.e10
FIG. 1. Hepatitis B core-related anti-
gen (HBcrAg) levels in the different
phases of chronic hepatitis B virus
(HBV) infection: hepatitis B e antigen
(HBeAg)-positive immune tolerance
(IT) phase, HBeAg-positive immune
clearance (IC) phase, HBeAg-negative
hepatitis (ENH) and HBeAg-negative
inactive/quiescent carrier phase
(ENQ). (a) Individual HBcrAg levels in
each phase with mean and standard
deviation (*p < 0.05; ****p < 0.0001).
(b) Proportion of patient HBcrAg
levels within certain ranges. (c) IC,
ENH and ENQ divided by the present
HBV genotype (GT) A or D.
606.e5 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIbetween HBcrAg levels and serum transaminases ALT and AST
as indicator for the intrahepatic inﬂammatory activity (r = 0.37
and 0.47; p = 0.0080 and 0.0072, respectively). In the ENH
cohort, we also documented a moderate negative correlation
between HBcrAg levels and serum albumin (r = −0.50; p =Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect0.0199) as well as platelet count (r = −0.40; p = 0.0229)
as indicators of the stage of liver disease. In HBeAg-positive
IC patients there was a weak, negative correlation with
bilirubin levels (r = −0.27; p = 0.0406) (Supplementary
Table S2).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 606.e1–606.e10
FIG. 2. Correlation between hepatitis B core-related antigen (HBcrAg) and hepatitis B virus (HBV) DNA serum levels in the different phases of HBV
infection (a) and further divided by the present HBV genotype (GT) A or D (b). r, Spearman’s correlation; r2, linear regression.
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We retrospectively collected follow-up data in 47 ENQ subjects
in whom at least a second follow-upwas available. A clinical event
either HBV reactivation (HBV DNA increase >1 log and to more
than 2000 IU/mL) and/or initiation of antiviral therapy for med-
ical reasons occurred in seven patients (17.5%) (median follow-
up, 29 months). Patients with a clinical event had a numerical
higher HBcrAg level at baseline (median: 2.78 log vs. 2.00 log U/
mL; p = 0.0794) (Supplementary Table S3). ROC curve analysis
identiﬁed an HBcrAg level of 3.87 log U/mL as the ideal cutoff.
Patients with an HBcrAg level <3.87 log U/mL had a signiﬁcantlyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inflower chance of experiencing a clinical event (p = 0.008; positive
predictive value 75%; negative predictive value 90.7%).
HBcrAg in acute hepatitis B
To further explore the role of HBcrAg in HBV infection, we
measured the marker in eight patients at several time points
during acute HBV infection. Median HBcrAg, HBV DNA and
HBsAg levels showed a similar pattern of decline during acute
HBV infection (Supplementary Figs. S1a and S2). All three
markers showed strong correlations with each other
(Supplementary Fig. S1b–d).ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 606.e1–606.e10
FIG. 3. Correlation between hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg) serum levels in the different phases of
hepatitis B virus (HBV) infection (a) and further divided by present HBV genotype (GT) A or D (b). r, Spearman’s correlation; r2, linear regression.
606.e7 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIDiscussionSerologic and molecular markers are key tools to understand-
ing and managing chronic HBV infection, i.e. in order to stratify
the risk for adverse outcomes (liver cirrhosis, HCC), to
determine the need for antiviral treatment and to monitor the
efﬁcacy of therapy. In this study, we showed in a large European
cohort that the absolute levels of HBcrAg and its correlationClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwith other HBV markers vary signiﬁcantly among the different
phases of the natural history of HBV infection.
We here documented that HBcrAg levels showed a strong
overall correlation with HBV DNA, suggesting that quantitative
HBcrAg might partly reﬂect virus replication. This is most
obvious in patients in the early acute phase of HBV infection,
where HBcrAg parallels with other HBV markers. However, we
found no correlation between HBV DNA and HBcrAg in the
ENQ phase, which is in contrast to recent results from an Asianious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 606.e1–606.e10
CMI Maasoumy et al. HBcrAg levels HBV infection 606.e8cohort [16]. This may be explained by the different HBV geno-
types between Europe and Asia (A/D vs. B/C). In contrast, we
found a moderate statistically signiﬁcant correlation between
HBcrAg and HBsAg in all phases of HBV infection also including
ENQ subjects. HBV DNA replication is a complex mechanism
that requires different independent pathways. For example, HBV
DNA replication and the production of viral proteins are not
necessarily linked to each other. While HBsAg can be synthe-
sized by using both cccDNA as well as smaller HBV DNA
fragments that are integrated into the host DNA, HBeAg and
HBcAg production require the presence of cccDNA including
the entire HBV genome [9]. Still, so far mostly HBsAg has been
suggested to be a surrogate marker for the amount of tran-
scriptional active cccDNA and the total number of infected
hepatocytes [11,17], although there have also been some
controversial reports in particular in HBeAg-negative cohorts
[18]. Among others, Suzuki et al. studied a possible link between
HBcrAg and cccDNA [19]. In both HBeAg-positive and -nega-
tive individuals, and even in patients with undetectable HBV
DNA in serum, they documented a signiﬁcant correlation be-
tween HBcrAg serum levels and the amount of intrahepatic
cccDNA [19]. Together with our results (correlation of HBcrAg
and HBsAg), these data indicate that HBcrAg may not only
reﬂect virus replication but also the activity in viral protein
production as a marker for the number of infected hepatocytes.
Recently, it has been shown that the highest HBsAg levels
are documented during the HBeAg-positive IT phase, followed
by the HBeAg-positive IC phase (5,6). Interestingly, we docu-
mented similar results for HBcrAg levels in our study, further
supporting a relation between these two markers. These data
are in line with recent observations in a large Asian cohort [16].
Not surprisingly, we detected HBcrAg in all HBeAg-positive (IT
and IC) patients, as the HBcrAg assay also measures HBeAg.
However, most ENH patients also tested positive for HBcrAg.
During the denaturation steps of the assay, immune complexes
of anti-HBe antibody and HBeAg are dissolved. Thus, HBeAg
may become detectable again. In addition, the HBcrAg assay
also identiﬁes HBcAg, which is of course also synthesized in
HBeAg-negative patients. Importantly, it has been shown that
the HBcrAg/HBcAg ratio is lower in HBeAg-negative patients,
suggesting that the HBcrAg assay more strongly reﬂects HBcAg
in these patients [20]. Indeed, in our study, we found detectable
HBcrAg in most of the ENH patients infected with an HBV
variant carrying the precore stop codon mutants (codon 28)
and conclusively unable to produce HBeAg—and importantly
also unable to produce p22cr. Thus, theoretically, the HBcrAg
assay should exclusively detect HBcAg in these patients.
Interestingly, we found no correlation between HBsAg and
HBcrAg in ENH patients with the precore wild-type HBV. A
possible explanation is that HBsAg only correlates with HBcAgClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infand not with HBeAg and p22cr in the ENH phase. Conversely,
we found a correlation between HBsAg and HBcrAg in HBeAg-
positive patients. More likely our results may be linked to the
present HBV genotype. Most precore stop mutants were found
in ENH patients infected with HBV genotype D. In all HBeAg-
negative patients, including ENQ subjects, we found a corre-
lation between HBcrAg and HBsAg only in those infected with
HBV genotype D and not in those with HBV genotype A.
In the past, there have been controversial ﬁndings regarding
the correlation between ALT levels as marker for hepatic
inﬂammation and HBcrAg [12,21]. However, none of these
studies differentiated among the phases of HBV infection. In our
study, we found that HBcrAg is linked to ALT and AST levels
only in the ENH phase, but not in ENQ or HBeAg-positive
patients. ALT and AST levels reﬂect the amount of liver cell
injury. Possibly liver cell death may allow HBV core particles to
enter the blood ﬂow, where they can be measured by the
HBcrAg assay. In HBeAg-positive patients, this effect on
HBcrAg levels might be attenuated by the unaffected presence
of HBeAg.
Interestingly, HBcrAg was undetectable or measured at very
low levels in most HBeAg-negative patients classiﬁed as ENQ,
suggesting low amounts of cccDNA or suppressed transcrip-
tional activity of cccDNA, thus leading to reduced virus repli-
cation in these patients. Similar ﬁndings were recently reported
from a large Asian cohort in which HBcrAg levels also appeared
to be useful in distinguishing between HBeAg-negative chronic
HBV infected patients with active and inactive disease [16].
Importantly, some patients in our study who were initially
classiﬁed as ENQ subjects by HBV DNA levels, ALT levels and/
or liver biopsy but with higher levels of HBcrAg (>3.87 log U/
mL) showed a signiﬁcantly increased chance for reactivation of
HBV during follow-up. This is in line with data from Japan,
where patients with higher HBcrAg levels after HBeAg sero-
conversion were at an increased risk of developing ENH [22].
Together, this indicates that HBcrAg might be a valuable
marker to identify HBV patients misclassiﬁed as inactive carriers
who require closer monitoring.
Our study has some important limitations, including its
cross-sectional design and the limited number of follow-up data
available for the ENQ subjects as well as the small number of
clinical events that could be observed. Thus, these data must be
conﬁrmed in larger, prospective cohorts. Furthermore, the
HBV genotype was not available for all patients. However,
although we do not have detailed information on ethnicity for
our cohort, most of the patients in our center are of European
origin. We excluded patients of known Asian origin from the
analysis. Thus, the number of Asian patients infected with HBV
genotypes B or C in our study should be minimal. However, a
small bias cannot be excluded.ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 606.e1–606.e10
606.e9 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIIn summary, HBcrAg levels vary signiﬁcantly during the
different phases of acute and chronic HBV infection in Euro-
pean patients primarily infected with HBV genotypes A and D.
HBcrAg may serve as valuable marker for virus replication in
HBeAg-positive individuals. In HBeAg-negative patients,
HBcrAg may help distinguish between inactive carriers and
those with active disease. Future studies are needed to further
determine the value of HBcrAg as a marker for the different
aspects of disease activity in chronic HBV infection, in particular
to investigate whether HBcrAg kinetics may predict immune
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